Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.57 |
| ▸ | ECE1 | P42892 | 2/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.56 |
| ▸ | CASP1 | P29466 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | CASP9 | P55211 | 2/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9697579 | 0.92 | MME (0.65) | MMEECE1FOLH1CASP1CASP3 | |
| SCHEMBL13323995 | 0.91 | MME (0.59) | MMEECE1FOLH1CASP1CASP3 | |
| SCHEMBL3054279 | 0.91 | MME (0.59) | MMEECE1FOLH1CASP1CASP3 | |
| SCHEMBL13324008 | 0.91 | MME (0.50) | MMEECE1FOLH1ACECTSL | |
| SCHEMBL3037401 | 0.91 | ACE (0.58) | MMEECE1ACECTSL | |
| SCHEMBL5689557 | 0.91 | ACE (0.58) | MMEECE1ACECTSL | |
| SCHEMBL13739666 | 0.91 | ACE (0.58) | MMEECE1ACECTSL | |
| SCHEMBL13324013 | 0.89 | ACE (0.61) | MMEECE1FOLH1ACECTSL | |
| SCHEMBL13324001 | 0.87 | MME (0.56) | MMEECE1CASP1CASP3CASP9 | |
| SCHEMBL5827209 | 0.87 | FOLH1 (0.65) | MMEECE1FOLH1CASP1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012153125-A1 | NOVEL COMPOUNDS AND METHODS FOR USE IN MEDICINE | ASTON UNIVERSITY (GB) | 2012-11-15 | — | — | WO | disclosed |
| US-7723307-B2 | Amino acid derivatives and pharmaceutical uses thereof | ASTON UNIVERSITY (GB) | 2010-05-25 | — | — | US | disclosed |
| US-7723307-B2 | Amino acid derivatives and pharmaceutical uses thereof | ASTON UNIVERSITY (GB) | 2010-05-25 | — | — | US | disclosed |
| US-20080200511-A1 | Novel Compounds and Methods of Using the Same | ASTON UNIVERSITY (GB) | 2008-08-21 | — | — | US | disclosed |
| US-20080200511-A1 | Novel Compounds and Methods of Using the Same | ASTON UNIVERSITY (GB) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200511-A1 | Novel Compounds and Methods of Using the Same | F3, IL4I1, TPMT | MME 2392/4885ECE1 3200/4885FOLH1 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.